This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Salix Pharmaceuticals Ltd (SLXP)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 1.16B 751.01M 292.81M 518.03M
Receivables 147.93M 268.24M 151.21M 140.18M
Inventories 104.40M 90.53M 49.20M 16.02M
Other Current Assets 0.00 0.00 0.00 0.00
Total Current Assets 2.30B 1.19B 567.10M 685.28M
Property, Plant & Equipment, Gross 48.66M 42.92M 41.24M 21.34M
Accumulated Depreciation & Depletion 21.34M 15.04M 11.70M 13.45M
Property, Plant & Equipment, Net 27.31M 27.88M 29.54M 7.90M
Intangibles 397.51M 441.51M 504.84M 64.58M
Other Non-Current Assets 37.55M 35.91M 21.88M 8.53M
Total Non-Current Assets 643.28M 686.20M 745.87M 166.26M
Liabilities & Shareholder Equity
Total Assets 2.94B 1.87B 1.31B 851.54M
Accounts Payable 32.63M 31.11M 21.14M 18.48M
Short Term Debt 47.00K 50.00K 188.00K 400.00K
Other Current Liabilities 290.19M 148.70M 108.92M 60.54M
Total Current Liabilities 420.53M 260.92M 210.65M 125.17M
Long Term Debt 1.63B 960.71M 459.98M 323.00M
Deferred Income Taxes 42.37M 64.26M 78.64M 0.00
Other Non-Current Liabilities 96.96M 20.84M 7.83M 0.00
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 1.78B 1.05B 552.69M 324.45M
Total Liabilities 2.20B 1.31B 763.33M 449.62M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 740.87M 560.50M 549.64M 401.92M
Common Par 63.00K 61.00K 59.00K 58.00K
Additional Paid In Capital 667.43M 631.36M 685.32M 624.89M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings 71.65M -71.38M -135.63M -223.02M
Treasury Stock 0.00 0.00 0.00 0.00
Other Equity Adjustments 1.72M 456.00K -111.00K 0.00
Total Capitalization 2.37B 1.52B 1.01B 724.92M
Total Equity 740.87M 560.50M 549.64M 401.92M
Total Liabilities & Stock Equity 2.94B 1.87B 1.31B 851.54M
Total Common Shares Outstanding 62.94M 60.92M 59.21M 58.14M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00 0.00
Basic Weighted Shares Outstanding 61.79M 58.75M 58.72M 57.30M
Diluted Weighted Shares Outstanding 65.69M 63.70M 65.48M 57.30M
Number of Employees 887 525 490 390
Number of Part-Time Employees 0 0 0 0
SLXP News

SLXP Salix Pharmaceuticals Ltd

Analysts Ratings for SLXP

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 8 12 9
Moderate Buy 0 0 0 0
Hold 6 6 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET SLXP ANALYST REPORT

Brokerage Partners

SLXP Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs